Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Will You Beat the Average $1,657 Social Security Benefit?
Will You Beat the Average $1,657 Social Security Benefit?

In 2022, retirees will receive an average Social Security benefit of $1,657. The $19,884 in yearly income this produces isn't exactly a generous amount of money to live on.

Some people, however, end

Morgan Stanley's Long-Term Financial Targets Make the Stock a Buy
Morgan Stanley's Long-Term Financial Targets Make the Stock a Buy

Morgan Stanley (NYSE: MS) had a phenomenal year in 2021, with its stock price rising about 43%. The investment bank and wealth manager achieved its internal guidance, and in many cases exceeded it

1 Stock to Buy Amid This Tech Sell-Off
1 Stock to Buy Amid This Tech Sell-Off

For investors focused solely on the broad market indexes, the last 12 months look pretty good relative to historical averages -- the S&P 500 and Dow Jones Industrial Average are both up by about 10%

Why GE's Results Aren't as Bad as the Market Thinks
Why GE's Results Aren't as Bad as the Market Thinks

Before Larry Culp took over as CEO of General Electric (NYSE: GE) in 2018, the company had a reputation for overpromising and underdelivering. The two previous CEOs left the company clinging to

Why Shares in Corning Soared Nearly 15% This Week
Why Shares in Corning Soared Nearly 15% This Week

Shares in material science company Corning (NYSE: GLW) rose nearly 15% in the week to Friday morning. The move comes after a very well-received set of fourth-quarter earnings released midweek.

This REIT's Results Suggest Office Demand Has Come Roaring Back
This REIT's Results Suggest Office Demand Has Come Roaring Back

Boston Properties (NYSE: BXP) is the country's largest publicly traded owner and developer of high-quality office properties. The real estate investment trust (REIT) concentrates on some of the

Why Hecla Mining Fell as Much as 12% This Week
Why Hecla Mining Fell as Much as 12% This Week

Shares of precious metals miner Hecla Mining (NYSE: HL) were lower by as much as 12% at one point this week according to data from S&P Global Market Intelligence. That's not a shock given that

This $22.5 Million Legal Loss Could Be a Huge Problem for This Dividend Aristocrat
This $22.5 Million Legal Loss Could Be a Huge Problem for This Dividend Aristocrat

There are only a few companies with the same kind of iconic history that 3M (NYSE: MMM), formerly Minnesota Mining and Manufacturing, has to offer. But a great history, including over six decades of

This Under-the-Radar SPAC Stock Is Quietly Crushing the Market. Is It a Buy in 2022?
This Under-the-Radar SPAC Stock Is Quietly Crushing the Market. Is It a Buy in 2022?

As of Monday, shares of Ranpak Holdings (NYSE: PACK) were up 163% since Dec. 13, 2018 -- the day it announced it was going public via a merger with a special purpose acquisition company (SPAC). By

Better Biotech Stock: CRISPR Therapeutics or Twist Bioscience?
Better Biotech Stock: CRISPR Therapeutics or Twist Bioscience?

CRISPR Therapeutics (NASDAQ: CRSP) focuses on modifying DNA. Twist Bioscience (NASDAQ: TWST) focuses on making DNA. Both companies' technologies appear to have tremendous potential. But which is the

Why Charles Schwab Is Still Acting Like a Growth Stock
Why Charles Schwab Is Still Acting Like a Growth Stock

There's been significant disruptionin the financial brokerage industry with Robinhood's incursion and no-fee trades going mainstream, but Charles Schwab (NYSE: SCHW) has continued to grow with the

What Microsoft's Big Deal Means for Metaverse Investors
What Microsoft's Big Deal Means for Metaverse Investors

Microsoft (NASDAQ: MSFT) has made no secret of the fact that its $70 billion acquisition of Activision Blizzard (NASDAQ: ATVI) is in part a bold bet on the metaverse.

In this video from "The Virtual

The Average Home Sold After Just 15 Days Last Year -- Will the Trend Continue?
The Average Home Sold After Just 15 Days Last Year -- Will the Trend Continue?

Housing set a lot of records last year. But one of the most shocking? That'd be the average 15-day selling time most properties saw, according to Redfin.

It's basically unheard of. Just five years

Apple's Rising, but This SaaS Stock's Rally Is More Important for Growth Investors
Apple's Rising, but This SaaS Stock's Rally Is More Important for Growth Investors

Investors haven't gotten much relief from the recent downturn in the stock market, and as the end of January approaches, it now appears likely that stocks will post their worst month since the

Stop Basing Your Retirement Savings on This Outdated Assumption
Stop Basing Your Retirement Savings on This Outdated Assumption

The type of retirement account you choose to invest in will make a huge impact in how you access your money -- and how much income your account provides -- once you become a senior.

Unfortunately

2 Software Stocks That Could Help Make You a Fortune
2 Software Stocks That Could Help Make You a Fortune

The last few months have been tough for owners of software companies. The iShares Tech-Software Sector ETF (NYSEMKT: IGV) is down 22% in the last three months alone, with many companies down close

1 Growth Stock Down 89% That Could Soar, According to Wall Street
1 Growth Stock Down 89% That Could Soar, According to Wall Street

For a long time, several high-growth companies have opted to prioritize market share over profitability. This means that many of these companies take a long time to reach breakeven and achieve

Why Macy's Stock Rose as Much as 18.5% This Week
Why Macy's Stock Rose as Much as 18.5% This Week

Shares of giant department store retailer Macy's (NYSE: M) had a good week, rising as much as 18.5% at one point, according to data from S&P Global Market Intelligence. It didn't hold on to all of

Is Pfizer About to Have Another Megablockbuster Drug in Its Lineup?
Is Pfizer About to Have Another Megablockbuster Drug in Its Lineup?

Pfizer (NYSE: PFE) already has at least eight products that generate annual sales of $1 billion or more. The U.S. Food and Drug Administration (FDA) recently approved another of Pfizer's drugs that

How Discover Is Gaining Market Share From Visa and Mastercard
How Discover Is Gaining Market Share From Visa and Mastercard

Discover Financial (NYSE: DFS) focuses on younger customers, like college students, with only minimal credit history. Though that may seem like a risky strategy, it's paid off for Discover. In this

2 Stocks That Turned $1,000 Into $10,000
2 Stocks That Turned $1,000 Into $10,000

Turning a $1,000 investment into $10,000 sounds like a feat, but over time, many stocks have achieved this. It's more incredible when it happens quickly, but slow and steady typically wins the

2 Top Metaverse Stocks to Buy and Hold for the Next 10 Years
2 Top Metaverse Stocks to Buy and Hold for the Next 10 Years

The world is abuzz about the metaverse, an evolving technology that could reshape life as we know it. While somewhat nebulous, the term is straight out of science fiction. It describes a network of

Start Your Investing Resolutions Off Right With This Classic Stock Bundle
Start Your Investing Resolutions Off Right With This Classic Stock Bundle

It's been a roller-coaster year for the stock market so far, and plenty of investors are questioning their strategy. Unfortunately, there's nothing you can really do to avoid volatility and market

Beyond Dogecoin and Shiba Inu: Buy This Unstoppable Growth Stock in 2022 Instead
Beyond Dogecoin and Shiba Inu: Buy This Unstoppable Growth Stock in 2022 Instead

Meme-investment mania took off like a rocket last year -- and with it, the prices of a number of cryptocurrencies. Prices of tokens like Dogecoin (CRYPTO: DOGE) and Shiba Inu (CRYPTO: SHIB) soared

Why Sorrento Therapeutics Stock Is Getting Hammered This Week
Why Sorrento Therapeutics Stock Is Getting Hammered This Week

Shares of clinical- and commercial-stage biotech Sorrento Therapeutics (NASDAQ: SRNE) plummeted by a whopping 36.8% during the first four trading sessions this week, according to data provided by